An expert editorial suggests that widely used diabetes and obesity drugs may help close the long-standing mortality gap faced by people with serious mental illnesses by tackling cardiovascular risk and metabolic disease head-on. Editorial: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have potential to transform health outcomes for persons with bipolar disorder, schizophrenia, major depressive disorder … Read more
The National Institute for Health and Care Excellence has recommended sparsentan (Filspari, Vifor Pharma) for treating primary immunoglobulin A nephropathy in adults. The recommendation reverses NICE’s February decision to reject NHS funding for the drug. The regulator had previously said available evidence did not demonstrate value for money. The manufacturer provided additional analyses and agreed to … Read more
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Carol H. Wysham, MD: Hello. I’m Dr Carol Wysham. Welcome to season 3 of the Medscape InDiscussion Type 2 Diabetes podcast series. Today, we’ll discuss chronic kidney … Read more
TOPLINE: Children exposed to maternal preeclampsia and born at term (37 weeks or more) were 26% more likely to develop kidney disease in the first year of life than those not exposed. They also faced notably high risks for chronic, unspecified, and diabetic kidney diseases as they grew older, particularly at or after 25 years … Read more
Sotagliflozin Shows Promise for Diabetes Management,Despite FDA Hurdles New research presented at the American Association of clinical Endocrinology (AACE) Annual Meeting 2025 suggests that sotagliflozin (Inpefa) can lower A1C levels and reduce body weight in individuals wiht type 2 diabetes. However, the benefits appear to be less pronounced in patients with moderate-to-severe chronic kidney disease … Read more
TOPLINE: Systematic home-based screening for albuminuria in primary care identified previously undiagnosed risk for chronic kidney disease (CKD), with greater participation among individuals invited by general practitioners (GPs). Overall, 8.7% of GP-invited participants had confirmed increased albuminuria, with 40.6% of them being newly diagnosed. METHODOLOGY: Researchers conducted a cross-sectional screening study to evaluate the effectiveness … Read more
TOPLINE: Regular use of glucosamine, a widely used supplement to manage osteoarthritis and joint pain, was linked to reduced risks for both composite microvascular complications and diabetic nephropathy among patients with type 2 diabetes (T2D). METHODOLOGY: Glucosamine, used daily by about 20% of US and Australian adults to treat osteoarthritis and joint pain, has been … Read more
Apr 9 2025 A sweeping global study finds that India, China, and the US will account for one-third of diabetes deaths and disabilities by 2050, unless urgent action is taken to curb the soaring rise of type 2 diabetes. Study: Comparative diabetes mellitus burden trends across global, Chinese, US, and Indian populations using GBD 2021 … Read more
Please note that the text below is not a full transcript and has not been copyedited. For more insight and commentary on these stories, subscribe to the This Week in Cardiology podcast, download the Medscape app or subscribe on Apple Podcasts, Spotify, or your preferred podcast provider. This podcast is intended for healthcare professionals only. … Read more
Updates on chronic kidney disease (CKD) diagnosis, use of sodium–glucose cotransporter-2 (SGLT-2) inhibitors as first-line therapy, and personalized treatment approaches for kidney and cardiovascular risk reduction are among the new CKD management recommendations from the Kidney Disease: Improving Global Outcomes (KDIGO) organization. “The last CKD guideline was published in 2012, and there have been so … Read more